|
1
|
Donepudi MS, Kondapalli K, Amos SJ and
Venkanteshan P: Breast cancer statistics and markers. J Cancer Res
Ther. 10:506–511. 2014.PubMed/NCBI
|
|
2
|
Gangadhara S, Barrett-Lee P, Nicholson RI
and Hiscox S: Pro-metastatic tumor-stroma interactions in breast
cancer. Future Oncol. 8:1427–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fazilaty H and Mehdipour P: Genetics of
breast cancer bone metastasis: A sequential multistep pattern. Clin
Exp Metastasis. 31:595–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khramtsov AI, Khramtsova GF, Tretiakova M,
Huo DZ, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation
is enriched in basal-like breast cancers and predicts poor outcome.
Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arend RC, Londono-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/beta-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Serafino A, Moroni N, Zonfrillo M,
Andreola F, Mercuri L, Nicotera G, Nunziata J, Ricci R, Antinori A,
Rasi G, et al: WNT-pathway components as predictive markers useful
for diagnosis, prevention and therapy in inflammatory bowel disease
and sporadic colorectal cancer. Oncotarget. 5:978–992. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu P, Tang H, Chen B, He Z, Deng M, Wu M,
Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour
proliferation and metastasis by targeting metadherin in triple
negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar
|
|
11
|
Chan SH, Huang WC, Chang JW, Chang KJ, Kuo
WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, et al: MicroRNA-149
targets GIT1 to suppress integrin signaling and breast cancer
metastasis. Oncogene. 33:4496–4507. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Y, Song YX and Wang ZN: The
microRNA-148/152 family: Multi-faceted players. Mol Cancer.
12:432013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing
C and Liu Z: Altered expression of miR-148a and miR-152 in
gastrointestinal cancers and its clinical significance. J
Gastrointest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang R, Li M, Zang W, Chen X, Wang Y, Li
P, Du Y, Zhao G and Li L: MiR-148a regulates the growth and
apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour
Biol. 35:837–844. 2014. View Article : Google Scholar
|
|
15
|
Liffers ST, Munding JB, Vogt M, Kuhlmann
JD, Verdoodt B, Nambiar S, Maghnouj A, Mirmohammadsadegh A, Hahn SA
and Tannapfel A: MicroRNA-148a is down-regulated in human
pancreatic ductal adenocarcinomas and regulates cell survival by
targeting CDC25B. Lab Invest. 91:1472–1479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Magrelli A, Azzalin G, Salvatore M,
Viganotti M, Tosto F, Colombo T, Devito R, Di Masi A, Antoccia A,
Lorenzetti S, et al: Altered microRNA expression patterns in
hepatoblastoma patients. Transl Oncol. 2:157–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar :
|
|
18
|
Yu J, Li Q, Xu Q, Liu L and Jiang B:
MiR-148a inhibits angiogenesis by targeting ERBB3. J Biomed Res.
25:170–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai
XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, et al: MiR-487a resensitizes
mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by
targeting breast cancer resistance protein (BCRP/ABCG2). Cancer
Lett. 339:107–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai X, Song Z, Fu Y, Yu Z, Zhao L, Zhao H,
Yao W, Huang D, Mi X, Wang E, et al: Clinicopathological
significance and prognostic value of DNA methyltransferase 1, 3a,
and 3b expressions in sporadic epithelial ovarian cancer. PLoS One.
7:e400242012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
22
|
Karim R, Tse G, Putti T, Scolyer R and Lee
S: The significance of the Wnt pathway in the pathology of human
cancers. Pathology. 36:120–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nusse R and Varmus HE: Many tumors induced
by the mouse mammary tumor virus contain a provirus integrated in
the same region of the host genome. Cell. 31:99–109. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong SC, Lo SF, Lee KC, Yam JW, Chan JK
and Wendy Hsiao WL: Expression of frizzled-related protein and
Wnt-signalling molecules in invasive human breast tumours. J
Pathol. 196:145–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wen Q, Zhao J, Bai L, Wang T, Zhang H and
Ma Q: miR-126 inhibits papillary thyroid carcinoma growth by
targeting LRP6. Oncol Rep. 34:2202–2210. 2015.PubMed/NCBI
|
|
26
|
Zhang W, Shen C, Li C, Yang G, Liu H, Chen
X, Zhu D, Zou H, Zhen Y, Zhang D, et al: miR-577 inhibits
glioblastoma tumor growth via the Wnt signaling pathway. Mol
Carcinog. Mar 12–2015.Epub ahead of print. View Article : Google Scholar
|
|
27
|
Subramanian M, Rao SR, Thacker P,
Chatterjee S and Karunagaran D: MiR-29b downregulates canonical Wnt
signaling by suppressing coactivators of beta-catenin in human
colorectal cancer cells. J Cell Biochem. 115:1974–1984.
2014.PubMed/NCBI
|
|
28
|
Yan H, Dong XG, Zhong XQ, Ye J, Zhou Y,
Yang X, Shen J and Zhang J: Inhibitions of epithelial to
mesenchymal transition and cancer stem cells-like properties are
involved in miR-148a-mediated anti-metastasis of hepatocellular
carcinoma. Mol Carcinog. 53:960–969. 2014.
|
|
29
|
Joshi P, Jeon YJ, Laganà A, Middleton J,
Secchiero P, Garofalo M and Croce CM: MicroRNA-148a reduces
tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc
Natl Acad Sci USA. 112:8650–8655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim J, Zhang Y, Skalski M, Hayes J, Kefas
B, Schiff D, Purow B, Parsons S, Lawler S and Abounader R:
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to
regulate EGFR and apoptosis in glioblastoma. Cancer Res.
74:1541–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
